Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00000106
Other study ID # NCRR-M01RR03186-9943
Secondary ID M01RR003186
Status Active, not recruiting
Phase N/A
First received January 18, 2000
Last updated June 23, 2005

Study information

Verified date November 2000
Source National Center for Research Resources (NCRR)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

Recently a non-toxic system for whole body hyperthermia (WBH) used at the University of Wisconsin has been shown to induce soluble tumor necrosis factor-receptor (sTNF-R) I and II when patients are heated systemically to 41.8C for 60 minutes. This observation might provide a biological basis for the therapeutic application of WBH to rheumatoid diseases, for which there is a positive anecdotal clinical experience. Inherent in the hypothesis which is the basis for this protocol is the concept that the induction of TNF receptors by WBH may induce a remission in patients with active rheumatoid arthritis. Beyond clinical response the biological endpoint for this investigation includes cytokine levels, TNF levels, sTNF-R levels and changes in cellular TNF receptors.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients are required to meet the criteria of the American College of Rheumatology (ACR)for rheumatoid arthritis.

- Patients should be in functional class II, or III according to the criteria of the ACR.

- All candidates must be unsuccessfully treated (lack of efficacy) with at least two of the following disease-modifying antirheumatic drugs: hydroxychloroquinine, oral or injectable gold, methotrexate, azathioprine, penicillamine, and sulfasalazine.

- Patients receiving nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroids (<= 10 mg per day), or both are eligible if the dosage has been stable for at least four weeks before treatment and remained so throughout the study and follow-up period (the use of narcotics for pain flares is allowed).

- The necessary degree of disease activity at enrollment should be confirmed by a finding of 10 or more swollen joints, 12 or more tender joints, and one of the following two criteria: a Westergren erythrocyte sedimentation rate of at least 28 mm per hour or a serum C-reactive protein level of more than 2.0 mg per deciliter; or morning stiffness for at least 60 minutes.

- Patients must have adequate bone marrow function, adequate liver function, adequate renal function, calcium and electrolytes.

- Patients must have a dobutamine stress ECHO, or exercise cardiac MUGA, or exercise ECHO scan prior to entry and must fulfill certain criteria to be eligible. The spirit of the criteria are to rule out organic heart disease.

- Respiratory status: Patients who have FEV1 of >= 60% of predicted, as well as a maximum voluntary volume (MVV) of >= 60% of predicted, and blood gases with a PO2 of >= 60 or oxygen saturation of >= 90% are eligible.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Whole body hyperthermia unit


Locations

Country Name City State
United States K4/666 CSC 600 Highland Av Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
National Center for Research Resources (NCRR)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Completed NCT02694796 - Impact of Web and Smartphone-based Physical Activity Program on Physical Activity Level 12 Months After a Balneotherapy N/A
Enrolling by invitation NCT02269254 - Persona Versus NexGen N/A
Completed NCT02256098 - RSA RCT: ATTUNEā„¢ TKA Versus PFC Sigma TKA N/A
Completed NCT00642837 - A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets Phase 4
Completed NCT02291471 - Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers Phase 1
Completed NCT01227694 - Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis Phase 1/Phase 2
Recruiting NCT01071447 - Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment N/A
Recruiting NCT02694185 - Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications N/A
Not yet recruiting NCT01006681 - Vaccination Against Influenza H1N1 in Rheumatic Diseases Phase 2
Not yet recruiting NCT03728231 - Disease Activity in RA and SLE Patients and Its Relation to Muscle Performance,Fatigue and Blood Parameters
Active, not recruiting NCT03371303 - Analysis of Changes in Medication Prescriptions After Hospitalization for 4 Disciplines: Gerontology, Diabetology, Cardiology and Rheumatology: Medical, Pharmaceutical and Economic Aspects N/A
Not yet recruiting NCT03492658 - Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA) Phase 4
Completed NCT02430402 - Rehabilitation of Young Patients With Rheumatic Diseases in a Warm Climate N/A
Enrolling by invitation NCT02717559 - Multicenter Orthopaedic Outcomes Network (MOON) ACL Reconstruction (ACLR): 10 Year Onsite Follow-up N/A
Completed NCT01656278 - An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis N/A
Completed NCT00665275 - Complementary and Alternative Medicine Among Outpatients With Inflammatory Rheumatic Diseases in Western Sweden N/A
Recruiting NCT03293719 - Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic
Not yet recruiting NCT03538470 - Assessment of the Effect of Spa Treatment on Rheumatological Conditions N/A
Enrolling by invitation NCT02508428 - Marathon and Enduron Polyethylene at Long-Term Follow-up N/A